NRIXNurix Therapeutics, Inc.

Nasdaq nurixtx.com


$ 24.43 $ 0.98 (4.18 %)    

Tuesday, 10-Sep-2024 15:59:39 EDT
QQQ $ 458.06 $ 4.20 (0.92 %)
DIA $ 408.23 $ -0.79 (-0.19 %)
SPY $ 548.63 $ 2.38 (0.44 %)
TLT $ 100.67 $ 0.70 (0.7 %)
GLD $ 232.64 $ 1.02 (0.44 %)
$ 24.42
$ 23.50
$ 24.41 x 100
-- x --
$ 23.50 - $ 24.43
$ 4.22 - $ 26.12
380,146
na
1.57B
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-11-2024 05-31-2024 10-Q
2 04-10-2024 02-29-2024 10-Q
3 02-15-2024 11-30-2023 10-K
4 10-12-2023 08-31-2023 10-Q
5 07-13-2023 05-31-2023 10-Q
6 04-13-2023 02-28-2023 10-Q
7 02-09-2023 11-30-2022 10-K
8 10-06-2022 08-31-2022 10-Q
9 07-07-2022 05-31-2022 10-Q
10 04-08-2022 02-28-2022 10-Q
11 01-28-2022 11-30-2021 10-K
12 10-14-2021 08-31-2021 10-Q
13 07-13-2021 05-31-2021 10-Q
14 04-13-2021 02-28-2021 10-Q
15 02-16-2021 11-30-2020 10-K
16 10-14-2020 08-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-30

Oppenheimer analyst Mark Breidenbach maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price targe...

 oppenheimer-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-27

Oppenheimer analyst Mark Breidenbach maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price targe...

 truist-securities-initiates-coverage-on-nurix-therapeutics-with-buy-rating-announces-price-target-of-36

Truist Securities analyst Srikripa Devarakonda initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and ...

 jp-morgan-maintains-overweight-on-nurix-therapeutics-raises-price-target-to-34

JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...

 barclays-maintains-overweight-on-nurix-therapeutics-raises-price-target-to-31

Barclays analyst Peter Lawson maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...

 rbc-capital-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-27

RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target f...

 needham-maintains-buy-on-nurix-therapeutics-lowers-price-target-to-29

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $31 to $29.

 nurix-says-enters-h2-of-2024-well-positioned-to-develop-lead-clinical-program-nx-5948-into-pivotal-clinical-trials-in-chronic-lymphocytic-leukemia-in-2025

Cash, cash equivalents and marketable securities was $452.5 million as of May 31, 2024, compared to $254.3 million as of Februa...

 nurix-therapeutics-q2-2024-gaap-eps-071-misses-063-estimate-sales-12092m-miss-22105m-estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of ...

 rbc-capital-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-26

RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target f...

 hc-wainwright--co-maintains-buy-on-nurix-therapeutics-raises-price-target-to-26

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price targ...

 whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

 jp-morgan-maintains-overweight-on-nurix-therapeutics-raises-price-target-to-31

JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION